There were 5271 prostate cancer patients included with 18 (0.3%) having germline BRCA1 alterations, 139 (2.6%) with BRCA2 alterations, 49 (0.9%) with germline ATM alterations, 15 (0.3%) with germline PALB2 alterations, and 27 (0.5%) with germline CHEK2 alterations. This evidence concerns the gene CHEK2 and prostate carcinoma.